Monitoring and Managing Adverse Events in Hemophilia Prophylaxis

Effective hemophilia management requires vigilant monitoring for adverse events associated with prophylactic therapies, including factor replacement, mimetics, and rebalancing agents. Clinicians implement structured follow-up, laboratory assessments, and patient-reported outcome tracking to identify side effects early and intervene promptly. Treatment discontinuation may be necessary in cases of severe reactions, inhibitor development, or intolerable side effects, with the next therapy chosen based on efficacy, safety profile, patient lifestyle, and prior response history. Patient counseling is essential, educating individuals on recognizing early signs of adverse events, self-monitoring, and reporting promptly. Guidelines, such as those from MASAC, provide evidence-based recommendations for managing complications, helping standardize care and ensure safe transitions between therapies. By combining proactive monitoring, patient education, and guideline-informed decision-making, clinicians can optimize treatment safety and maintain quality of life for people with hemophilia.